CN103710302B - Prepare method and the special culture media combination thereof of pancreatic stem cells - Google Patents
Prepare method and the special culture media combination thereof of pancreatic stem cells Download PDFInfo
- Publication number
- CN103710302B CN103710302B CN201210371241.8A CN201210371241A CN103710302B CN 103710302 B CN103710302 B CN 103710302B CN 201210371241 A CN201210371241 A CN 201210371241A CN 103710302 B CN103710302 B CN 103710302B
- Authority
- CN
- China
- Prior art keywords
- culture medium
- cell
- solute
- stem cells
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001963 growth medium Substances 0.000 title claims abstract description 179
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 163
- 238000000034 method Methods 0.000 title claims abstract description 37
- 210000004027 cell Anatomy 0.000 claims abstract description 114
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims abstract description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 26
- 230000006698 induction Effects 0.000 claims description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 23
- 239000008103 glucose Substances 0.000 claims description 23
- 239000007640 basal medium Substances 0.000 claims description 21
- 238000012360 testing method Methods 0.000 claims description 21
- 108010023082 activin A Proteins 0.000 claims description 17
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 13
- 239000006228 supernatant Substances 0.000 claims description 12
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 10
- 239000003797 essential amino acid Substances 0.000 claims description 10
- 235000020776 essential amino acid Nutrition 0.000 claims description 10
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 10
- 229930002330 retinoic acid Natural products 0.000 claims description 10
- 229960001727 tretinoin Drugs 0.000 claims description 10
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 claims description 8
- 238000012549 training Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims description 6
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims description 5
- 238000007796 conventional method Methods 0.000 claims description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 238000011534 incubation Methods 0.000 claims description 4
- 235000005152 nicotinamide Nutrition 0.000 claims description 4
- 239000011570 nicotinamide Substances 0.000 claims description 4
- 229960003966 nicotinamide Drugs 0.000 claims description 4
- 150000001408 amides Chemical class 0.000 claims description 3
- 238000012546 transfer Methods 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 abstract description 39
- 108090000623 proteins and genes Proteins 0.000 abstract description 34
- 210000004039 endoderm cell Anatomy 0.000 abstract description 20
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 14
- 210000003890 endocrine cell Anatomy 0.000 abstract description 10
- 210000003020 exocrine pancreas Anatomy 0.000 abstract description 10
- 230000009996 pancreatic endocrine effect Effects 0.000 abstract description 10
- 241000700159 Rattus Species 0.000 abstract description 9
- 210000000496 pancreas Anatomy 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 208000027418 Wounds and injury Diseases 0.000 abstract description 4
- 230000006378 damage Effects 0.000 abstract description 4
- 208000014674 injury Diseases 0.000 abstract description 4
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 208000024691 pancreas disease Diseases 0.000 abstract description 3
- 238000002054 transplantation Methods 0.000 abstract description 3
- 238000013459 approach Methods 0.000 abstract description 2
- 238000002659 cell therapy Methods 0.000 abstract description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 40
- 238000001514 detection method Methods 0.000 description 25
- 108090001061 Insulin Proteins 0.000 description 23
- 230000004069 differentiation Effects 0.000 description 21
- 102000004877 Insulin Human genes 0.000 description 20
- 229940125396 insulin Drugs 0.000 description 20
- 101150057663 Foxa2 gene Proteins 0.000 description 16
- 108010065511 Amylases Proteins 0.000 description 14
- 101710183548 Pyridoxal 5'-phosphate synthase subunit PdxS Proteins 0.000 description 13
- 238000002372 labelling Methods 0.000 description 13
- 241000283707 Capra Species 0.000 description 12
- 239000004382 Amylase Substances 0.000 description 11
- 102000013142 Amylases Human genes 0.000 description 11
- 235000019418 amylase Nutrition 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 108010075254 C-Peptide Proteins 0.000 description 9
- 230000003321 amplification Effects 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 8
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 8
- 101100310648 Mus musculus Sox17 gene Proteins 0.000 description 8
- 238000011529 RT qPCR Methods 0.000 description 8
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 108010080937 Carboxypeptidases A Proteins 0.000 description 7
- 238000012797 qualification Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 108060003199 Glucagon Proteins 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000004043 dyeing Methods 0.000 description 6
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 5
- 101800001586 Ghrelin Proteins 0.000 description 5
- 102400000442 Ghrelin-28 Human genes 0.000 description 5
- 101150084866 MAFA gene Proteins 0.000 description 5
- 108010056088 Somatostatin Proteins 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 238000012757 fluorescence staining Methods 0.000 description 5
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 5
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- GRHBQAYDJPGGLF-UHFFFAOYSA-N isothiocyanic acid Chemical compound N=C=S GRHBQAYDJPGGLF-UHFFFAOYSA-N 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
- 210000002955 secretory cell Anatomy 0.000 description 5
- 101150084750 1 gene Proteins 0.000 description 4
- 102000000496 Carboxypeptidases A Human genes 0.000 description 4
- 102100039501 Chymotrypsinogen B Human genes 0.000 description 4
- 101710147853 Chymotrypsinogen B Proteins 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002247 constant time method Methods 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 101150076489 B gene Proteins 0.000 description 3
- 108010038061 Chymotrypsinogen Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 101150036261 HNF1B gene Proteins 0.000 description 3
- 108700014808 Homeobox Protein Nkx-2.2 Proteins 0.000 description 3
- 102100028098 Homeobox protein Nkx-6.1 Human genes 0.000 description 3
- 101000578254 Homo sapiens Homeobox protein Nkx-6.1 Proteins 0.000 description 3
- 101000911772 Homo sapiens Hsc70-interacting protein Proteins 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 101000607573 Mus musculus Unknown protein from 2D-PAGE of fibroblasts Proteins 0.000 description 3
- 101150074224 Onecut1 gene Proteins 0.000 description 3
- 101150111723 PDX1 gene Proteins 0.000 description 3
- 101150106167 SOX9 gene Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 3
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000001427 coherent effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 210000003771 C cell Anatomy 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241000192700 Cyanobacteria Species 0.000 description 2
- 101100451304 Danio rerio hnf1ba gene Proteins 0.000 description 2
- 101100518002 Danio rerio nkx2.2a gene Proteins 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 2
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 2
- 102100025304 Integrin beta-1 Human genes 0.000 description 2
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 101100096235 Xenopus laevis sox9-a gene Proteins 0.000 description 2
- 101100096236 Xenopus laevis sox9-b gene Proteins 0.000 description 2
- 101100043970 Xenopus tropicalis sox17a gene Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000002478 diastatic effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 1
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- 101150087690 ACTB gene Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- 210000004128 D cell Anatomy 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 101100129232 Danio rerio mafaa gene Proteins 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 description 1
- 101001060261 Homo sapiens Fibroblast growth factor 7 Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101150051019 Klrg1 gene Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 208000016222 Pancreatic disease Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000011316 allogeneic transplantation Methods 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 210000002907 exocrine cell Anatomy 0.000 description 1
- 230000004204 exocrine pancreatic function Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000013394 immunophenotyping Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 238000012528 insulin ELISA Methods 0.000 description 1
- 229950004152 insulin human Drugs 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000029052 metamorphosis Effects 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 230000010003 pancreatic endocrine function Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N phosphoric acid Substances OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical class OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Abstract
The present invention relates to prepare the method for pancreatic stem cells and special culture media combination thereof.Specifically, the invention discloses a kind of method inducing human mesenchymal stem cell to obtain pancreatic stem cells and the combination of supporting culture medium thereof.Method of the present invention can the most once obtain limited endoderm cell and pancreatic stem cells through two one-step inducing methods, each phase cell can express corresponding specific gene, and the pancreatic stem cells finally obtained can break up pancreatic endocrine cell and the Exocrine Pancreas In Rats becoming meritorious energy.The pancreatic stem cells that the present invention obtains may be used for treating the injury of pancreas that the diseases such as diabetes cause, and the cell therapy for injury of pancreas disease provides experimental basis and Clinical Evidence, provides new approach for cellular transplantation therapy.
Description
Technical field
The present invention relates to a kind of method preparing pancreatic stem cells and special culture media combination thereof.More specifically,
The present invention relates to a kind of utilize special culture media combination by mescenchymal stem cell induction be pancreatic stem cells method and
This special culture media combines.
Background technology
Diabetes have become the multiple and metabolic disease of refractory in the whole world, are the easy heaps of the glucose in a kind of blood
Long-pending too much disease.Abroad give its another name " reticent killer " (Silent Killer).Particularly " adult type
Diabetes ", it is the highest that the middle age of more than 40 years old catches rate.In Japan, in the population of more than 40 years old 10%
Containing this disease, in the middle of i.e. ten people, just there is " diabetes " patient.Once suffer from " diabetes ", the life-span ten will be reduced
More than Nian, thereby increases and it is possible to the complication of generation is throughout whole body.
For many years, medical circle is devoted to the research to diabetes always.This is because once suffer from " diabetes ", people
The trouble of body will come one after another, owing to immunologic function weakens, human body easily infect by cold virus, streptococcus pneumoniae,
The various infectious disease that pulmonary bacillus etc. are caused, and be difficult to cure.These diseases and optionally
Destroy cell, phagocyte.The defensive enginery of inhibiting tumor cell can weaken significantly, causes cancerous cell to enliven, assembles.
No wonder having such saying, once obtained " diabetes ", the life-span deducts more than ten years.Therefore diabetes are talked by many people
And complexion changed, carrying out by every possible means is treated.
Diabetes (Diabetes) point type 1 diabetes, type 2 diabetes mellitus, gestational diabetes and the sugar of other specific types
Urine disease.Its morbidity relates to the many factors such as inherited genetic factors, environmental factors, and with hypoinsulinism and pancreas
Insulin resistance is main performance.
Insulin is unique blood sugar lowering hormone in the health that human pancreas's B cell is secreted.Insulin is by islets of langerhans β
Cell is by endogenous or the thorn of exogenous material such as glucose, lactose, ribose, arginine, glucagon etc.
A kind of proteohormone swashed and secrete.Insulin is the hypoglycemic hormone of unique fall in body, simultaneously facilitates sugar
Former, fatty, protein synthesis.Exogenous insulin is mainly used in treating diabetes, and diabetics makes in early days
It is expected to that the long period occurs with insulin and superpower antioxidant (such as injection thioctic acid, oral astaxanthin etc.)
Honeymooners, injection of insulin does not have addiction and dependency.
Pancreatic stem cells is tissue specifc stem cells, and it can be divided into all types of pancreatic cell,
Thus can be as the potential donor's cells of pancreatic diseases damaging cells replacement therapy.But, pancreatic stem cells
It is difficult to obtain from pancreatic tissue and expand in vitro.Pancreas is obtained as seed cell using mescenchymal stem cell
Gland stem cell will not limited by cell derived.
Stem cell is a kind of germinal cell with self-renewal capacity and polyphyly differentiation potential, is cell transplantation
Preferable cell.In ontogenetic process, there is various forms of stem cell, such as embryonic stem cell, how competent
Committed stem cell in cell and various tissue, such as hematopoietic stem cell, neural stem cell etc., but should in reality
Use the challenge but facing ethics or the restriction drawn materials.Mescenchymal stem cell (MSC) is present in tissue
In there is a kind of Subaerial blue green algae group of polyphyly differentiation potential, can be induced to differentiate into many in certain circumstances because of it
Kind of histiocyte, and have that immunogenicity is low, transplant after can form the features such as the most chimeric, therefore can be as one
Preferably for the cell of allotransplantation.Because MSC Subaerial blue green algae can obtain the differentiation of inside embryonic tissue
Potential ability, easily draw materials, the more horn of plenty and do not limited by ethics and do not become tumor dangerous of originating, therefore use
Derived mesenchymal stem cells in vitro induction obtains pancreatic stem cells and has higher using value clinically.
The present invention intends developing a kind of culture medium combination and methodology the most directionally to be lured by mescenchymal stem cell
Lead as pancreatic stem cells, thus the treatment for diabetes and complication thereof provides a kind of new selection.
Summary of the invention
Therefore, the technical purpose of the present invention is that seeking one can be by mescenchymal stem cell directional induction in vitro
The method of activated pancreatic stem cells and the combination of corresponding culture medium.
Therefore, a first aspect of the present invention relates to a kind of culture medium C, and it is by zooblast basal medium and solute
Composition；Described solute and the concentration in zooblast basal medium thereof are as follows: 0.50 × 10-5mol/L-2.0×
10-5Mol/L retinoic acid, 10ng/ml-30ng/ml EGF, 10ng/ml-100ng/ml bFGF, 20ng/ml-200ng/ml
Dkk1,0.2mmol/L-10mmol/L glutamine, volume ratio be 0.2%-5% non essential amino acid and can
The B27 that volume ratio is 0.5%-5% of choosing；Preferably, 0.95 × 10-5mol/L-1.05×10-5Mol/L retinoic acid,
19ng/ml-21ng/ml EGF、32ng/ml-64ng/ml bFGF、80ng/ml-120ng/ml Dkk1、
1.9mmol/L-2.1mmol/L the non essential amino acid that glutamine, volume ratio are 0.95%-1.05% and optional
The B27 that volume ratio is 1.9%-2.1%；And wherein said zooblast basal medium is DMEM in high glucose
Culture medium or DMEM/F12 culture medium.
Preferably, described culture medium C is made up of DMEM/F12 culture medium and solute；Described solute and
Concentration in culture medium B is as follows: 10-5Mol/L retinoic acid, 20ng/ml EGF, 60ng/ml bFGF, 100ng/ml
Dkk1,2mmol/L glutamine, volume ratio be 1% non essential amino acid and optional volume ratio be 2%
B27.
A second aspect of the present invention relates to a kind of by the test kit that mescenchymal stem cell induction is pancreatic stem cells, its
It is made up of culture medium A, culture medium B and culture medium C, wherein
Described culture medium A is made up of zooblast basal medium and solute；Described solute and at zooblast
Concentration in basal medium is as follows: 1.00ml/L-20.00ml/L hyclone, 1.00ng/mL-15.00ng/mL
Activin A and 10-200ng/mL wnt3a；Preferably, 4.75ml/L-5.25ml/L hyclone,
4.75ng/mL-5.25ng/mL activin A and 40-60ng/mL wnt3a；
Described culture medium B is made up of zooblast basal medium and solute；Described solute and at zooblast
Concentration in basal medium is as follows: 1.00ml/L-20.00ml/L hyclone and 1.00ng/mL-15.00ng/mL
activin A；Preferably, 4.75ml/L-5.25ml/L hyclone and 4.75ng/mL-5.25ng/mL activin A
Described culture medium C is as described in above-mentioned first aspect；
And wherein said zooblast basal medium is DMEM in high glucose culture medium or DMEM/F12 cultivation
Base.
Preferably, described culture medium A is made up of DMEM in high glucose culture medium and solute；Described solute and training
Support the concentration in base A as follows: 5ml/L hyclone, 5ng/mL activinA and 5ng/mL wnt3a；
Described culture medium B is made up of DMEM in high glucose culture medium and solute；Described solute and in culture medium A
In concentration as follows: 5ml/L hyclone and 5ng/mL activin A；
Described culture medium C is as described in above-mentioned first aspect.
Preferably, described the test kit that mescenchymal stem cell induction is pancreatic stem cells is also included culture medium D
Or E, wherein:
Culture medium D is made up of DMEM in high glucose culture medium and solute；Described solute and in culture medium D
Concentration is as follows: 5ml/L hyclone, 20ng/ml exendin-4,10ng/ml activin A, 10mmol/L Buddhist nun
Gram amide, volume ratio be 2% B27 and volume ratio be the N2 of 1%；
Culture medium E is made up of DMEM in high glucose culture medium and solute；Described solute and dense in culture medium E thereof
Spend as follows: 5ml/L hyclone, 20ng/ml exendin-4,15ng/ml FGF7,10mmol/L niacin amide,
Volume ratio be 2% B27 and volume ratio be the N2 of 1%.
Preferably, described mescenchymal stem cell is fat mesenchymal stem cell, it is preferable that described mesenchyme is dry thin
Born of the same parents are the 3rd generation mescenchymal stem cell.
A third aspect of the present invention relates to a kind of by the method that mescenchymal stem cell induction is pancreatic stem cells, its bag
Include step: by mescenchymal stem cell successively with the culture medium A in the test kit described in claim 3 or 4, training
Support the culture medium C described in base B and claim 1 or 2 to cultivate, obtain pancreatic stem cells, Qi Zhongsuo
Stating mescenchymal stem cell uses conventional method to obtain.
Preferably, described method comprises the steps:
1) mescenchymal stem cell that conventional method obtains is inoculated in described culture medium A, cultivates 1d；
2) cell completing step 1) is transferred in described culture medium B, cultivate 4-5d；
3) step 2 will be completed) cell transfer in described culture medium C, cultivate 4-6d, obtain pancreatic stem thin
Born of the same parents.
Preferably, in described step (1), described mescenchymal stem cell initial concentration in described culture medium A
It is 2 × 105Individual/ml-1 × 106Individual/ml；In described method, the condition of culture of whole incubation is: 37 DEG C,
50ml/L CO2, relative air humidity be 95% incubator in cultivate.
Preferably, described method also comprises the steps:
The pancreatic stem cells obtained is separately added into culture medium D or culture medium E, every hole 2000 μ L, 37 DEG C,
50ml/L CO2, relative air humidity be 95% incubator in cultivate 8d, every 2d inhale abandon supernatant and add
2000 culture medium D new for μ L or E.
It is pancreatic stem cells according to above-mentioned being induced by mescenchymal stem cell that a fourth aspect of the present invention relates to a kind of
The pancreatic stem cells that method obtains.
In other words, it is an object of the invention to provide a kind of side utilizing mescenchymal stem cell to prepare pancreatic stem cells
Method and special culture media combination thereof.
The method for inducing and cultivating of the present invention is applicable to the mescenchymal stem cell of various tissue-derived each generation.This lures
Lead the virus-free importing of cultural method, easily operation, efficiency height.The method for inducing and cultivating of the present invention is first with routine
Method obtains the mescenchymal stem cell of certain tissue-derived (such as fatty tissue or myeloid tissue), then utilizes training
Support base A and B and cultivate the mescenchymal stem cell of above-mentioned acquisition, obtain limited endoderm cell, in this is limited
Endoderm cell expresses limited entoderm mark Foxa2, Sox17, it is thus achieved that efficiency can reach more than 95%；With
After utilize culture medium C to cultivate to obtain pancreatic stem cells, described pancreatic stem cells expresses pancreatic stem cells mark Pdx1,
Obtain efficiency and can reach more than 90%, pancreatic stem cells positive for Pdx1 can not only vitro differentiation for there being function
Pancreatic endocrine cell, and can vitro differentiation be to have the Exocrine Pancreas In Rats of function, this mark is also
Judge that the cell that the present invention is obtained is the quality standard of pancreatic stem cells.Wherein culture medium A consists of high sugar
DMEM culture medium, 4.75ml/L-5.25ml/L hyclone, 4.75ng/mL-5.25ng/mL activin A and
40-60ng/mL wnt3a；Culture medium B consists of DMEM in high glucose culture medium, 4.75ml/L-5.25ml/L tire cattle
Serum, 4.75ng/mL-5.25ng/mL activin A；Culture medium C consist of DMEM/F12 culture medium, 0.95
×10-5mol/L-1.05×10-5Mol/L retinoic acid, 19ng/ml-21ng/ml EGF, 32ng/ml-64ng/ml
FGF2(bFGF), 80ng/ml-120ng/mL Dkk1,1.9mmol/L-2.1mmol/L glutamine, volume
It is the B27 of 1.9%-2.1% than non essential amino acid and the optional volume ratio for 0.95%-1.05%.This area skill
Art personnel understand, the most specifically illustrate the culture medium composition of above-mentioned two concentration of height all in the embodiment of the present application
In the case of realizing the present invention well, the concentration range of described culture medium can be to lower concentration and Geng Gao
Concentration carry out suitable extension after remain to realize technical purpose of the present invention.The lowest or higher concentration
The technique effect of the culture medium of composition may be better than, is equal to or is inferior to the experimental result indicated by the embodiment of the present application,
But as long as can realize the technical purpose that the induction of described mescenchymal stem cell is pancreatic stem cells, the most such proportioning
Culture medium still fall within the scope of protection of present invention.
Can be sketched by the step of mescenchymal stem cell acquisition pancreatic stem cells and be: the fatty tissue that fat absorption method is obtained
Clean and obtain after conventional digestion the cell of separation, the cell of above-mentioned acquisition is seeded in equipped with expansion with suitable density
Increase in the Tissue Culture Flask of culture fluid, obtain the 1st, 2,3 generation mescenchymal stem cells, the 3rd will obtained successively
The most sequentially it is placed in culture medium A for mescenchymal stem cell and cultivates 1d, culture medium B cultivation 4-6d, culture medium C
Cultivate 4-6d, finally obtain pancreatic stem cells.Those skilled in the art know, the above-mentioned training listed by the present invention
The method step supported and induce is only the purpose of illustration, may not realize the preferred plan of the method for the invention,
Said method step can be made suitable change and remain to realize the purpose of the present invention by those skilled in the art,
Such change also falls into the scope of protection of present invention.Certainly, fill between the method for the invention is used
Matter stem cell is not limited to the 3rd generation mescenchymal stem cell, and the mescenchymal stem cell of other generations can also use.
So-called 3rd generation mescenchymal stem cell refers to the mescenchymal stem cell in the 3rd fat subsitutes source, and described mesenchyme is dry thin
Born of the same parents can be adipose-derived mescenchymal stem cell can also be other source mescenchymal stem cells.Described amplification
Culture fluid is not limited to the amplification cultivation liquid that the present invention is specifically used, the amplification training that other mescenchymal stem cells are suitable for
Nutrient solution all can use.
Therefore, mescenchymal stem cell through two one-step inducing methods can the most once obtain limited endoderm cell,
Pancreatic stem cells, each phase cell can express corresponding specific gene, and the pancreatic stem cells obtained has
Differentiation becomes pancreatic endocrine cell and the function of Exocrine Pancreas In Rats of meritorious energy.
The pancreatic stem cells that the inventive method obtains can be applicable to treat the injury of pancreas that the diseases such as diabetes cause,
Cell therapy for injury of pancreas disease provides experimental basis and Clinical Evidence, provides for cellular transplantation therapy
New approach.
Accompanying drawing explanation
Fig. 1: for the form of human mesenchymal stem cell (seed cell of pancreatic stem cells).
Fig. 2: for the immunophenotype testing result of human mesenchymal stem cell (seed cell of pancreatic stem cells).Respectively
The top of accompanying drawing indicates the immunophenotype type of correspondence.
Fig. 3: for the form of the limited endoderm cell that the differentiation of people's derived mesenchymal stem cells in vitro obtains.
Fig. 4: for the immunocyte fluorescence dye of the limited endoderm cell that the differentiation of people's derived mesenchymal stem cells in vitro obtains
Color testing result.A is the cell after using culture medium A inducing culture, and B is the 3rd generation mescenchymal stem cell.
Fig. 5: for the real-time quantitative PCR of the limited endoderm cell that the differentiation of people's derived mesenchymal stem cells in vitro obtains
Testing result.
Fig. 6: for the form of the pancreatic stem cells that limited endoderm cell's vitro differentiation obtains.
Fig. 7: for the immunocyte fluoroscopic examination knot of the pancreatic stem cells that limited endoderm cell's vitro differentiation obtains
Really.A is the limited endoderm cell that the 3rd generation mescenchymal stem cell induction obtains, and B is for using culture medium C
Cell after inducing culture.
Fig. 8: the pancreatic stem cells cell real-time quantitative PCR inspection obtained for limited endoderm cell's vitro differentiation
Survey result.
Fig. 9: for the immunity of the pancreatic endocrine secretory cell that pancreatic stem cells/pancreatic progenitor cell vitro differentiation obtains
Cell fluorescence dyeing testing result.A is the Pdx1 positive cell that the 3rd generation mescenchymal stem cell induction obtains, B
For the cell after employing culture medium D inducing culture.
Figure 10: for the real-time quantitative PCR detection knot of the pancreatic endocrine cell that pancreatic stem cells vitro differentiation obtains
Really.
Figure 11: for the insulin secretion total amount detection of the pancreatic endocrine cell that pancreatic stem cells vitro differentiation obtains
Result.
Figure 12: for the insulin releasing situation detection of the pancreatic endocrine cell that pancreatic stem cells vitro differentiation obtains
Result.
Figure 13: for the immunocyte fluorescence dye of the exocrine pancreas secretory cell that pancreatic stem cells vitro differentiation obtains
Color testing result.A is the Pdx1 positive cell that the 3rd generation mescenchymal stem cell induction obtains, and B cultivates for using
Cell after base E inducing culture.
Figure 14: for the real-time quantitative PCR detection knot of the Exocrine Pancreas In Rats that pancreatic stem cells vitro differentiation obtains
Really.
Figure 15: for the amylase secretion total amount detection of the Exocrine Pancreas In Rats that pancreatic stem cells vitro differentiation obtains
Result.
Detailed description of the invention
Below example facilitates a better understanding of the present invention, but is not meant to for limiting the present invention.Following
Experimental technique in embodiment, if no special instructions, is conventional method.Test used in following embodiment
Material, if no special instructions, is and is commercially available from routine biochemistry reagent shop.Determining in following example
Amount test, is respectively provided with three times and repeats experiment, results averaged.
Embodiment
Embodiment 1 experiment material
Penicillin, streptomycin and trypsin-EDTA are purchased from GIBCO company.Trizol is purchased from American I nvitrogen
Company, Oligo dT, M-MLV reverse transcriptase, Taq archaeal dna polymerase, dNTP and RNase inhibitor are purchased
From Takara company of Japan.
Mouse anti human Foxa2 monoclonal antibody, rabbit anti-human Insulin monoclonal antibody, rabbit anti-human C-peptide polyclone
Antibody, rabbit anti-human AMY monoclonal antibody are purchased from Abcam company of the U.S..Goat anti human's Sox17 monoclonal anti
Body, Goat anti human's pdx1 monoclonal antibody are purchased from R&D company of the U.S..Chicken anti-mouse IgG of isothiocyanic acid labelling,
Chicken anti-rabbit IgG of isothiocyanic acid labelling, rhodamine labelling donkey anti goat igg purchased from Santa cruz company, sieve
The red goat anti-mouse IgG of bright labelling, the goat anti-rabbit igg of rhodamine labelling, the little mouse-anti of isothiocyanic acid labelling
Goat IgG is purchased from Beijing company of Zhong Shan Golden Bridge.
Embodiment 2, the preparation of culture medium
DMEM/F12 culture medium (also known as DF12 culture medium) and DMEM in high glucose culture medium are purchased from GIBCO
Company.Hyclone (FCS) is purchased from GIBCO company.Niacin amide is purchased from Sigma company.Glutamine
Purchased from GIBCO company, catalog number is 25030-081.Retinoic acid is purchased from Sigma company, catalogue
Number it is R2625.
Human activin A(ActivinA) purchased from Pepro Tech company of Britain, catalog number is 120-14.
EGF (epidermal growth factor, epithelical cell growth factor) is purchased from Pepro Tech company, product
Catalog number (Cat.No.) is 100-15.
BFGF (basic fibroblast growth factor, basic fibroblast growth factor) is public purchased from Sigma
Department, catalog number is F0291.
Exendin-4 is purchased from Sigma company, and catalog number is E7144.
FGF7 is purchased from Pepro Tech company, and catalog number is 100-19.
DKK1 is purchased from R&D company, and catalog number is 5439-DK-010.
B27 is purchased from GIBCO company, and catalog number is 17504-044.
N2 is purchased from GIBCO company, and catalog number is 17502-048.
Non essential amino acid is purchased from GIBCO company, and catalog number is 11140.
Following culture medium A-C is all configured by low content and high-load.
Culture medium A is made up of DMEM in high glucose culture medium and solute；Described solute and in culture medium A
Concentration is as follows: 4.75ml/L(is low) or 5.25ml/L(high) hyclone, 4.75ng/mL(be low) or 5.25ng/mL
(high) activinA and 40ng/mL(is low) or 60ng/mL(height) wnt3a..
Culture medium B is made up of DMEM in high glucose culture medium and solute；Described solute and in culture medium B
Concentration is as follows: 4.75ml/L(is low) or 5.25ml/L(high) hyclone, 4.75ng/mL(be low) or 5.25ng/mL
(high) activinA.
Culture medium C is made up of DMEM/F12 culture medium and solute；Described solute and dense in culture medium C thereof
Spend as follows: 0.95 × 10-5Mol/L(is low) or 1.05 × 10-5Mol/L(is high) retinoic acid, 19ng/ml(be low)
Or 21ng/ml(is high) EGF, 32ng/ml(be low) or 64ng/ml(high) FGF2(bFGF), 80ng/ml
(low) or 120ng/mL(are high) Dkk1,1.9mmol/L(be low) or 2.1mmol/L(high) glutamine,
Volume ratio is that 0.95%(is low) or 1.05%(high) non essential amino acid and volume ratio be that 1.9%(is low) or
2.1%(is high) B27.Wherein, retinoic acid, FGF2, EGF, Dkk1, glutamine and non-essential amino
Acid is for obtaining composition necessary to pancreatic stem cells.
Culture medium D is made up of DMEM in high glucose culture medium and solute；Described solute and in culture medium D
Concentration is as follows: 5ml/L hyclone, 20ng/ml exendin-4,10ng/ml activin A, 10mmol/L Buddhist nun
Gram amide, volume ratio be 2% B27 and volume ratio be the N2 of 1%.
Culture medium E is made up of DMEM in high glucose culture medium and solute；Described solute and dense in culture medium E thereof
Spend as follows: 5ml/L hyclone, 20ng/ml exendin-4,15ng/ml FGF7,10mmol/L niacin amide,
Volume ratio be 2% B27 and volume ratio be the N2 of 1%.
Embodiment 3, the sequential inducing culture of insulin human secretory cell
Step one, preparation the 3rd generation mescenchymal stem cell
1, fat absorption method fatty tissue D-Hanks that gathers out will be used ' (can also use PBS) wash away blood
Cell and anesthetics, 0.2%II Collagenase Type 37 DEG C digestion 30min, 100 eye mesh screens filter and collect filtrate.
2, the cell obtained by D-Hank ' the resuspended step 1 of s liquid repeated washing 2 times are to remove collagenase, room temperature
1200rpm is centrifuged 10min, collects cell.
3, by the cell of step 2 with 2 × 106The density of individual/ml is inoculated in equipped with the amplification cultivation liquid (example of formula
One of be containing 58%DF12,40%MCDB, 2% hyclone, 1 × 10-9MITS、1×10-9M ground plug rice
Pine, 1 × 10-4M2-phosphoric acid ascorbic acid, 20ng/mL interleukin-6,10ng/mL EGF, 10ng/mL
PDGF-BB, 100U/mL penicillin and 100 μ g/mL streptomycins, other have the expansion of similar effect certainly
Increase culture fluid the most all can use) T75 Tissue Culture Flask in, at 37 DEG C, 50ml/L CO2, air relative
Humidity be 95% incubator cultivate (24-48hr) after 36hr and discard culture fluid (cell containing the most adherent),
And supplementing new amplification cultivation liquid, the most every 3d partly measures the amplification cultivation liquid more renewed, when cell reaches 70%-80%
When converging, with 1g/L trypsin Gibco company) conventional digestion, cell passes on according to 1:3,
To 1st generation mesenchymal cell.
4,1st generation mesenchymal cell is cultivated in amplification cultivation liquid 2-3d(at 37 DEG C, 50ml/L CO2, empty
Gas relative humidity is the incubator cultivation of 95%), reach 70%-80% and converge, wash 2 times with D-Hank ' s liquid, use
1g/L trypsin Gibco company) conventional digestion, cell passes on according to 1:3, obtains between 2nd generation
Mesenchymal cells.
5,2nd generation mesenchymal cell is cultivated in amplification cultivation liquid 2-3d(at 37 DEG C, 50ml/L CO2, empty
Gas relative humidity be 95% incubator cultivate), reach 70%-80% and converge, wash 2 times with D-Hank ' s liquid, so
Afterwards with the trypsin Gibco company of 1g/L) conventional digestion, room temperature 1200rpm is centrifuged 6min, collects thin
Born of the same parents.
6, by the cell of step 5 with 1 × 106The density in individual/hole is inoculated in 6 orifice plates equipped with amplification cultivation liquid and (purchases
From Nunclon company) in, at 37 DEG C, 50ml/L CO2, relative air humidity be 95% incubator cultivate
4-6hr, reject culture medium after cell attachment, wash 2 times with D-Hank ' s, be denoted as the 3rd generation mescenchymal stem cell.
Certainly, the present invention can also use the isolated culture method of other mescenchymal stem cells well known in the art
Obtain the 3rd generation mescenchymal stem cell or directly use commercially available 3rd generation mescenchymal stem cell and without from
Row separation and Culture obtains.
Step 2, employing culture medium combination carry out sequential inducing culture
1, the cultivation of first stage
(1) in 6 orifice plates, add culture medium A (to note that and employ high concentration and two proportionings of low concentration
Culture medium A, culture medium B and C below are also such), every hole 2000 μ L.
(2) in 6 orifice plates of step (1), the 3rd generation mescenchymal stem cell is inoculated so that it is in the medium
Concentration is 6 × 105Individual/ml, at 37 DEG C, 50ml/L CO2, relative air humidity be 95% incubator in train
Support 1d.
(3) inhale the culture medium A in 6 orifice plates abandoning step (2), add culture medium B(every 2d suction and abandon supernatant
And add 2000 culture medium B new for μ L).
2, the cultivation of second stage
The supernatant in 6 orifice plates of first stage step (3) is abandoned in suction, adds culture medium C, every hole 2000 μ L,
37℃、50ml/L CO2, relative air humidity be 95% incubator in cultivate the every 2d of 4-6d(inhale abandon supernatant also
Add 2000 culture medium C new for μ L).
3, the cultivation of phase III
Inhale the supernatant abandoned in 6 orifice plates of second stage, be separately added into culture medium D or culture medium E, every hole 2000 μ L,
At 37 DEG C, 50ml/L CO2, relative air humidity be 95% incubator in cultivate the every 2d of 8d(inhale abandon supernatant
And add 2000 culture medium D new for μ L or E), room temperature 1200rpm is centrifuged 6min, collects cell (precipitation).
(being combined as: A → B → C → D or E) (uses D and E culture medium respectively merely to prove the pancreas obtained
Stem cell has the function being divided into ripe Exocrine cells.After the sequential use being induced to culture medium C the completeest
Cheng Liao.)
Step 3, (following experimental result is all that the culture medium A of low concentration, B, C are carried out in the qualification of inducing effect
The result of induction)
1, the values of immunophenotyping of the 3rd generation mescenchymal stem cell
The cellular morphology of the 3rd generation mescenchymal stem cell that step one obtains is shown in Fig. 1.
By the phenotype of indirect immunofluorescence detection the 3rd generation mescenchymal stem cell, with Fluorescein isothiocyanate (FITC)
Mouse anti human CD29 of labelling, CD34, CD44, CD73, CD90, CD105, CD106, CD117,
Flow cytometer detection is carried out, stream after Flk-1, HLA-ABC and HLA-DR antibody (antibody is purchased from BD company) labelling
Formula cell instrument is ACCURI C6 (Becton Dickinson).
Result is shown in that Fig. 2, abscissa represent that cell fluorescence intensity, vertical coordinate represent cell number；P2 represents selected thin
Born of the same parents colony.Phenotypic results shows, the CD29 of the 3rd generation mescenchymal stem cell, CD44, CD73, CD90,
CD105, Flk-1 and HLA-ABC are the positive, and CD34, CD106, CD117 and HLA-DR molecule is equal
For feminine gender.Compared with prior art, the peculiar phenotype of the mescenchymal stem cell that the present invention is obtained is that Flk-1 is positive.
2, human mesenchymal stem cell is induced to differentiate into the qualification of limited endoderm cell
(1) identification of morphology
In culture medium A and B, cultivate cell after 6d reach 80%-90% and converge, the form of cell in incubation
Change as follows: cultivating 1-2d, cell is essentially fusiformis, and minority is cobblestone sample epithelial cell form, and fusiformis is thin
The percentage ratio of born of the same parents is more than 90%；After cultivating 4-6d, cell volume significantly increases, and arrangement is tight, spindle cell ratio
Example reduces, and most cells present cobblestone sample epithelial cell form, and the percentage ratio of cobblestone like cell is more than 90%,
The cell cultivating 5d in culture medium A and B is shown in Fig. 3.
(2) immunofluorescence dyeing is identified
The cell (using the 3rd generation mescenchymal stem cell as comparison) cultivating 5d in the 1 of step 2 is carried out immunity
Fluorescence staining, detects the expression of limited entoderm mark Foxa2 and Sox17.
The concrete grammar of detection Foxa2 is as follows: cell is fixed with 80% ice ethanol, with containing 1%BSA after PBS
PBST buffer blind；Then with mouse anti human Foxa2 monoclonal antibody (working concentration is 1:50 dilution)
As anti-incubated at room 1hr；After cleaning with PBS, then with isothiocyanic acid (green fluorescence) labelling
Goat anti-mouse IgG is as two anti-incubated at room 30min；Hoechst33342 is used after cleaning with PBS
Dyeing liquor (Sigma) redyes nucleus (blue-fluorescence), at fluorescence microscopy Microscopic observation (Olympus).3rd
Green fluorescence is not the most shown, for negative findings for mescenchymal stem cell.Use after culture medium A inducing culture is thin
Born of the same parents more than 90% show green fluorescence.
The concrete grammar of detection Sox17 is essentially identical with the concrete grammar of detection Foxa2, and difference is only that employing
Goat anti human's Sox17 monoclonal antibody (working concentration is 1:100 dilution) resists as one, uses rhodamine (red
Color fluorescence) labelling mice anti goat igg as two resist.3rd generation mescenchymal stem cell does not the most show red glimmering
Light, for negative findings.The cell more than 90% after culture medium A inducing culture is used to show red fluorescence.
Result is shown in Fig. 4 (A is the cell after using culture medium A inducing culture, and B is the 3rd generation mescenchymal stem cell).
Result shows, after employing culture medium A inducing culture, most cells is Foxa2 and Sox17 is positive.
(3) Real-time PCR Analysis
Take the cell (using the 3rd generation mescenchymal stem cell as comparison) cultivating 5d in the 1 of step 2, extract total
RNA reverse transcription are cDNA, identify Foxa2 gene and the expression of Sox17 gene by real-time quantitative PCR
Situation.Using people GAPDH as the comparison of each gene, primer used is as follows:
For expanding the primer of Foxa2 gene it is:
Forward primer: 5 '-CTGAGCGAGATCTACCAGTGGA-3 ' (SEQ ID NO:1)；
Downstream primer: 5 '-CAGTCGTTGAAGGAGAGCGAGT-3 ' (SEQ ID NO:2).
For expanding the primer of Sox17 gene it is:
Forward primer: 5 '-GCATGACTCCGGTGTGAATCT-3 ' (SEQ ID NO:3)；
Downstream primer: 5 '-TCACACGTCAGGATAGTTGCAGT-3 ' (SEQ ID NO:4).
For expanding the primer of GAPDH it is:
Forward primer: 5 '-GGTCACCAGGGCTGCTTTTA-3 ' (SEQ ID NO:5)；
Downstream primer: 5 '-GAGGGATCTCGCTCCTGGA-3 ' (SEQ ID NO:6).
Use△△CT method calculates the relative expression quantity of each gene.Foxa2 gene with the 3rd generation mescenchymal stem cell
The expression of (or sox17 gene) is 1, calculates in the cell after using culture medium A and B inducing culture each
The relative expression quantity of individual gene.Use in the cell after culture medium A and the sequential inducing culture of B, foxa2 gene
Relative expression quantity is 15.43, and the relative expression quantity of sox17 gene is 4.70.Result is shown in Fig. 5.
Above qualification result shows, uses the cell after culture medium A and B inducing culture mainly to behave limited interior
Endoderm cell (as it has been described above, have expressed the specificity marker gene of limited endoderm cell, and shows limit
The form of qualitative endoderm cell).
3, limited endoderm cell is divided into the qualification of pancreatic stem cells
(1) identification of morphology
In culture medium C cultivate 6d, in incubation, the metamorphosis of cell is as follows: cell taper into and in
Bulk coherent condition.The cell cultivating 6d in culture medium C is shown in Fig. 6.
(2) immunofluorescence dyeing is identified
The cell (using the 3rd generation mescenchymal stem cell as comparison) cultivating 6d in the 2 of step 2 is carried out immunity
Fluorescence staining, detection pancreatic stem cells mark Pdx1 and limited endoderm cell indicate the expression of Foxa2 respectively
Situation.
The concrete grammar of detection Pdx1 is essentially identical with the concrete grammar of detection Foxa2, and difference is only that employing mountain
Goat-anti people's Pdx1 monoclonal antibody (working concentration is 1:100 dilution) resists as one.3rd generation mesenchyme is dry thin
Born of the same parents the most do not show red fluorescence, for negative findings.The cell after culture medium C inducing culture more than 90% is used to show
Show red fluorescence.
Result is shown in that (A is the limited endoderm cell that the 3rd generation mescenchymal stem cell induction obtains to Fig. 7, and B is for adopting
Cell with after culture medium C inducing culture).Result shows, uses most cells after culture medium C inducing culture
Positive for Pdx1 immunocyte fluorescence staining.
(3) Real-time PCR Analysis
Take the cell (using the 3rd generation mescenchymal stem cell as comparison) cultivating 6d in the 2 of step 2, extract total
RNA reverse transcription are cDNA, identified respectively by real-time quantitative PCR Pdx1, P48, Sox9, Hnf6,
The expression of Hnf1b, Nkx6.1 and Nkx2.2 gene.Use people GAPDH as the comparison of each gene,
Primer used is as follows:
For expanding the primer of Pdx1 it is:
Forward primer: 5 '-TACTGGATTGGCGTTGTTTGTGGC-3 ' (SEQ ID NO:7)；
Downstream primer: 5 '-AGGGAGCCTTCCAATGTGTATGGT-3 ' (SEQ ID NO:8).
For expanding the primer of P48 it is:
Forward primer: 5 '-TTCACCGACCAGTCTTCACG-3 ' (SEQ ID NO:9)；
Downstream primer: 5 '-GTGGCTAAGGAACTCCACCT-3 ' (SEQ ID NO:10).
For expanding the primer of Sox9 it is:
Forward primer: 5 '-GGCGGAGGAAGTCGGTGAAG-3 ' (SEQ ID NO:11)；
Downstream primer: 5 '-GGGTGCGGTGCTGCTGAT-3 ' (SEQ ID NO:12).
For expanding the primer of Hnf6 it is:
Forward primer: 5 '-TGTGGAAGTGGCTGCAGGA-3 ' (SEQ IDNO:13)；
Downstream primer: 5 '-TGTGAAGACCAACCTGGGCT-3 ' (SEQ ID NO:14).
For expanding the primer of Hnf1b it is:
Forward primer: 5 '-GCACCTCTCCCAGCATCTCA-3 ' (SEQ IDNO:15)；
Downstream primer: 5 '-GTCGGAGGATCTCTCGTTGC-3 ' (SEQ ID NO:16).
For expanding the primer of Nkx6.1 it is:
Forward primer: 5 '-AGAGAGTCAGGTCAAGGTCTGGTT-3 ' (SEQ ID NO:17)；
Downstream primer: 5 '-TGTCTCCGAGTCCTGCTTCTTCTT-3 ' (SEQ IDNO:18).
For expanding the primer of Nkx2.2 it is:
Forward primer: 5 '-GACAACTGGTGGCAGATTTCGCTT-3 ' (SEQ ID NO:19)；
Downstream primer: 5 '-AGCCACAAAGAAAGGAGTTGGACC-3 ' (SEQ IDNO:20).
For expanding the primer of GAPDH it is:
Forward primer: 5 '-GGTCACCAGGGCTGCTTTTA-3 ' (SEQ ID NO:5)；
Downstream primer: 5 '-GAGGGATCTCGCTCCTGGA-3 ' (SEQ ID NO:6).
Use△△CT method calculates the relative expression quantity of each gene.Pdx1 gene with the 3rd generation mescenchymal stem cell
(or p48 gene or sox9 gene or hnf6 gene or hnf1b gene or nkx6.1 gene or nkx2.2 gene)
Expression be 1, calculate and use the relative expression quantity of each gene in the cell after culture medium C inducing culture.Adopt
With in the cell after culture medium C inducing culture, the relative expression quantity of pdx1 gene is 49.53, the phase of p48 gene
Being 58.04 to expression, the relative expression quantity of sox9 gene is 2.24, and the relative expression quantity of hnf6 gene is 4.30,
The relative expression quantity of hnf1b gene is 24.41, and the relative expression quantity of nkx6.1 gene is 6.50, nkx2.2 gene
Relative expression quantity be 17.71.Result is shown in Fig. 8.Result shows, after using culture medium C to cultivate, and human mesenchyme
Pancreatic stem cells gene Pdx1, endoderm and the pancreatic precursor of the limited endoderm cell of source of human stem cell
The expression of cytogene P48, Sox9, Hnf6, Hnf1b, Nkx6.1 and Nkx2.2 gene is all raised.Above
Qualification result shows, after using culture medium C inducing culture, the cell in bulk coherent condition is pancreatic stem cells
(this cell expresses pancreatic stem cells specificity marker gene, and demonstrates bulk coherent condition, and this cell enters
One one-step inducing can obtain pancreatic endocrine cell and Exocrine Pancreas In Rats).
4, pancreatic stem cells vitro differentiation is the qualification of pancreatic endocrine cell
(1) immunofluorescence dyeing is identified
The cell (using the 3rd generation mescenchymal stem cell as comparison) cultivating 8d in the 3 of step 2 is carried out immunity
Fluorescence staining, detection endocrine cell mark insulin (Insulin) and the expression of C peptide (C-peptide).
The concrete grammar of detection insulin is essentially identical with the concrete grammar of detection Foxa2, and difference is only that employing
Rabbit anti-Human Insulin's monoclonal antibody (working concentration is 1:50 dilution) resists as one, uses isothiocyanic acid (green
Color fluorescence) labelling goat anti-rabbit igg as two resist.3rd generation mescenchymal stem cell does not the most show green fluorescence,
For negative findings.The cell more than 95% after culture medium D inducing culture is used to show green fluorescence.
The concrete grammar of detection C peptide is essentially identical with the concrete grammar of detection Foxa2, and difference is only that employing rabbit
Anti-C-P polyclonal antibody (working concentration is 1:100 dilution) resists as one, uses rhodamine (red glimmering
Light) labelling goat anti-rabbit igg as two resist.3rd generation mescenchymal stem cell does not the most show red fluorescence, for
Negative findings.The cell more than 95% after culture medium D inducing culture is used to show red fluorescence.
Result is shown in that (A is the Pdx1 positive cell that the 3rd generation mescenchymal stem cell induction obtains to Fig. 9, and B is for using
Cell after culture medium D inducing culture).Result shows, uses most cells after culture medium D inducing culture
Positive for insulin and C peptide.
(3) Real-time PCR Analysis
Take the cell in the 3 of step 2, the 3rd generation mesenchyme (is done by the cell cultivating 8d in culture medium D
Cell is as comparison) to extract total serum IgE reverse transcription be cDNA, identifies insulin base by real-time quantitative PCR
Cause, glucagon gene, somatostatin gene, pancreatic polypeptide (Pan-pol) gene, ghrelin gene, MafA
Gene and the expression of Glut-2 gene.Use people GAPDH as the comparison of each gene, primer used
As follows
For expanding the primer of insulin gene it is:
Forward primer: 5 '-AGAGGCCATCAAGCAGATCACTGT-3 ' (SEQ ID NO:21)；
Downstream primer: 5 '-CACAGGTGTTGGTTCACAAAGGCT-3 ' (SEQ ID NO:22).
For expanding the primer of glucagon gene it is:
Forward primer: 5 '-TCTTGATAATCTTGCCGCCAGGGA-3 ' (SEQ ID NO:23)；
Downstream primer: 5 '-CATGCAAAGCAATGTGGCCTCAGA-3 ' (SEQ ID NO:24).
For expanding the primer of somatostatin gene it is:
Forward primer: 5 '-TGAACCCAACCAGACGGAGAATGA-3 ' (SEQ ID NO:25)；
Downstream primer: 5 '-GAAATTCTTGCAGCCAGCTTTGCG-3 ' (SEQ ID NO:26).
For expanding the primer of Pan-pol gene it is:
Forward primer: 5 '-AAAGACACAAAGAGGACACGCTGG-3 ' (SEQ ID NO:27)；
Downstream primer: 5 '-TCGTAGGAGACAGAAGGTGGCATT-3 ' (SEQ ID NO:28).
For expanding the primer of ghrelin gene it is:
Forward primer: 5 '-AAGTGATCGCCCACAAGCCTTACT-3 ' (SEQ ID NO:29)；
Downstream primer: 5 '-TGTACAACAGTCGTGGGAGTTGCT-3 ' (SEQ ID NO:30).
For expanding the primer of MafA gene it is:
Forward primer: 5 '-CTTCAGCAAGGAGGAGGTCATC-3 ' (SEQ ID NO:31)；
Downstream primer: 5 '-CTCGTATTTCTCCTTGTACAGGTCC-3 ' (SEQ ID NO:32).
For expanding the primer of Glut-2 gene it is:
Forward primer: 5 '-AGCTGCATTCAGCAATTGGACCTG-3 ' (SEQ ID NO:33)；
Downstream primer: 5 '-ATGTGAACAGGGTAAAGGCCAGGA-3 ' (SEQ ID NO:34).
For expanding the primer of GAPDH it is:
Forward primer: 5 '-GGTCACCAGGGCTGCTTTTA-3 ' (SEQ ID NO:5)；
Downstream primer: 5 '-GAGGGATCTCGCTCCTGGA-3 ' (SEQ ID NO:6).
Use△△CT method calculates the relative expression quantity of each gene.Insulin gene with the 3rd generation mescenchymal stem cell
(or glucagon gene or somatostatin gene or Pan-pol gene or ghrelin gene or MafA gene or
Glut-2 gene) expression be 1, calculate and use the phase of each gene in the cell after culture medium D inducing culture
To expression.Using in the cell after culture medium D inducing culture, the relative expression quantity of insulin gene is 6.39,
The relative expression quantity of glucagon gene is 2.17, and the relative expression quantity of somatostatin gene is 39.60, Pan-pol
The relative expression quantity of gene is 1.42, and the relative expression quantity of ghrelin gene is 3.22, the relative table of MafA gene
The amount of reaching is 7.66, and the relative expression quantity of Glut-2 gene is 8.22.Result is shown in Figure 10.Result shows, uses training
After supporting base D cultivation, the pancreatic stem cells in fat mesenchymal stem cell source expresses pancreatic endocrine function cell phase
Correlation gene insulin gene, glucagon gene, somatostatin gene, pancreatic polypeptide gene (Pan-pol), ghrelin,
MafA and Glut-2.
(4) insulin secretion function detection
1. insulin assay
The cell of 8d will be cultivated (using the 3rd generation mescenchymal stem cell as right through culture medium D in the 3 of step 2
According to) test as follows:
For each cell hole, take all culture supernatant, and the cell in this hole is counted.By in cultivation
Clear 2000rpm is centrifuged 10min, take supernatant and with insulin ELISA detection kit (EZHIASF-14K,
MILLIPORE) detection insulin content (concrete operations are carried out according to test kit description).
Every 6 × 105The insulin total amount that emiocytosis after the induction of individual employing culture medium D obtains is (373.37 ± 8.47)
(20.14 ± 4.81) μ U/ml, the insulin total amount that the 3rd generation mescenchymal stem cell secretion obtains is (20.14 ± 4.81)
μ U/ml(P ＜ 0.01).Result is shown in Figure 11.
2. cell C-peptide secretory function measures
By in the 3 of step 2 through culture medium D cultivate 8d cell test as follows:
By 5 × 105After individual cell PBS washs 3 times, in 1mL KRBH buffer, hatch 6hr
(3-6hr), cell is placed in the 1mL KRBH buffer containing 5.5mM glucose and hatches 1hr, collects supernatant
Liquid (solution first)；Again cell is placed in the 1mL KRBH buffer containing 22mM glucose and hatches 1hr, collect
(collecting supernatant here to need not be centrifuged, simply cell counting needs centrifugal counting to supernatant (solution second), centrifugal
Condition is 1200rpm, 6min).
C peptide ELISA kit (EZHCP-20K, MILLIPORE) is used to detect solution first and solution respectively
The content (concrete assay method reference reagent box description) of C peptide in second.
In solution first, C peptide emission levels is (203.98 ± 15.68) pmol/L/h (P < 0.05), this level representation pancreas
Island element de novo synthesis amount.In solution second, C peptide emission levels reaches (325.23 ± 14.37) pmol/L/h(P ＜ 0.05).
Result is shown in Figure 12.Result shows, uses the cell after the induction of culture medium D to have in vitro glucose response
Insulin secretion function.Result shows, using the cell after culture medium D inducing culture is insulin secretory cell
(this cell expresses insulin secretory cell specificity marker gene, and demonstrate the ability of secreted in vitro insulin
And the reactivity to glucose).
4, pancreatic stem cells vitro differentiation is the qualification of Exocrine Pancreas In Rats
(1) immunofluorescence dyeing is identified
The cell (using the 3rd generation mescenchymal stem cell as comparison) cultivating 8d in the 3 of step 2 is carried out immunity
Fluorescence staining, detects the diastatic expression of Exocrine Pancreas In Rats mark.
Detecting diastatic concrete grammar essentially identical with the concrete grammar of detection Foxa2, difference is only that employing
Rabbit anti-human amylase monoclonal antibody (working concentration is 1:50 dilution) resists as one, uses rhodamine (red
Fluorescence) labelling goat anti-rabbit igg as two resist.3rd generation mescenchymal stem cell does not the most show red fluorescence,
For negative findings.The cell more than 95% after culture medium C inducing culture is used to show red fluorescence.
Result is shown in that (A is the Pdx1 positive cell that the 3rd generation mescenchymal stem cell induction obtains to Figure 13, and B is for using
Cell after culture medium E inducing culture).Result shows, after using culture medium E inducing culture, most cells is
Amylase positive.
(3) Real-time PCR Analysis
Take the cell in the 3 of step 2, culture medium E is cultivated the cell of 8d (by dry for the 3rd generation mesenchyme thin
Born of the same parents are as comparison), extract total serum IgE and reverse transcription is cDNA, identify gene starch by real-time quantitative PCR
Enzyme (AMY), elastoser 1, Carboxypeptidase A (CPA) and the expression of chymotrypsinogen B (CTRB).
Using people GAPDH as the comparison of each gene, primer used is as follows:
For expanding the primer of amylase gene it is:
Forward primer: 5 '-CTTTGTGGATAACCATGACAATCAA-3 ' (SEQ ID NO:35)；
Downstream primer: 5 '-CAACTGCCATTTTGTACAGCCTAG-3 ' (SEQ ID NO:36).
For expanding the primer of elastoser 1 gene it is:
Forward primer: 5 '-AGCACAACCTGAGCCAGAAT-3 ' (SEQ ID NO:37)；
Downstream primer: 5 '-TTGTTAGCCAGGATGGTTCC-3 ' (SEQ ID NO:38).
For expanding the primer of Carboxypeptidase A gene it is:
Forward primer: 5 '-ACTACGCCACCTACCACACC-3 ' (SEQ ID NO:39)；
Downstream primer: 5 '-GGTGTTGCCAATCTGGATCT-3 ' (SEQ ID NO:40).
For expanding the primer of chymotrypsinogen 1 B gene it is:
Forward primer: 5 '-GAACTGGCTTCCATTTCTGC-3 ' (SEQ ID NO:41)；
Downstream primer: 5 '-ATGTCATTACGCACGGTGAA-3 ' (SEQ IDNO:42).
For expanding the primer of GAPDH it is:
Forward primer: 5 '-GGTCACCAGGGCTGCTTTTA-3 ' (SEQ ID NO:5)；
Downstream primer: 5 '-GAGGGATCTCGCTCCTGGA-3 ' (SEQ ID NO:6).
UseΔΔCT method calculates the relative expression quantity of each gene.Amylase gene with the 3rd generation mescenchymal stem cell
The table of (or elastoser 1 gene or Carboxypeptidase A gene or chymotrypsinogen 1 B gene or ACTB gene)
The amount of reaching is 1, calculates the relative expression quantity of each gene in the cell after using culture medium E inducing culture.Use training
Supporting in the cell after base E inducing culture, the relative expression quantity of amylase gene is 6.45, elastoser 1 base
The relative expression quantity of cause is 9.28, and the relative expression quantity of Carboxypeptidase A gene is 4.89, chymotrypsinogen 1 B gene
Relative expression quantity be 4.79.Result is shown in Figure 14.Result shows, after using culture medium E to cultivate, fills between fat
Pancreatic stem cells exocrine pancreatic function cell relating gene-1 amylase (AMY) of matter source of human stem cell, elastic egg
White enzyme 1, Carboxypeptidase A (CPA) and chymotrypsinogen B (CTRB) express and raise.
(4) amylase secretion Function detection
The cell (using the 3rd generation mescenchymal stem cell as comparison) of 8d will be cultivated through culture medium E in the 3 of step 2
Test as follows:
For each cell hole, take all culture supernatant, and the cell in this hole is counted.By in cultivation
Clear 2000rpm is centrifuged 10min, takes supernatant and (has with amylase ELISA detection kit detection amylase content
Gymnastics is made to carry out according to test kit description).
Every 6 × 105The amylase total amount that emiocytosis after the induction of individual employing culture medium E obtains is (82.55 ± 1.01)
μM, the insulin total amount that the 3rd generation mescenchymal stem cell secretion obtains is (27.23 ± 0.93) μM (P ＜ 0.05).
Result is shown in Figure 15.
Third generation mesenchyme is done by above the results show employing culture medium A of the present invention, B and C
Cell the most disposably obtains limited endoderm cell after carrying out sequential induction and pancreatic stem is thin
Born of the same parents, each phase cell can express corresponding specific gene, and the pancreatic stem cells finally obtained can break up
Become pancreatic endocrine cell and the Exocrine Pancreas In Rats having function.Simultaneously with the culture medium A of high concentration, B and
The result that C carries out sequential induction is quite similar with the result carrying out inducing with the culture medium A of low concentration, B and C,
Do not repeat them here.
As well known to those skilled in the art, can be to culture medium A of the present invention, the composition of B, C, D and E
Composition (the especially constituent of culture medium A, B and C) and concentration are made various change and are remained to realize this
Invent technique effect required for protection, such as in order to make mescenchymal stem cell grow more quickly or more permanently
Maintain its phenotype, can add corresponding somatomedin such as HGF in the medium, or other nutrients such as β-
Mercaptoethanols etc., the concentration of the various solutes in described culture medium can also be lower or higher.Although carrying out so
Adjustment after, the using effect of described culture medium may be deteriorated, but as long as it can realize the purpose of the present invention
The most within the scope of the present invention.
Claims (10)
1., by the test kit that mescenchymal stem cell induction is pancreatic stem cells, it is by culture medium A, culture medium
B and culture medium C composition, wherein
Described culture medium A is made up of zooblast basal medium and solute；Described solute and at zooblast
Concentration in basal medium is as follows: 1.00ml/L-20.00ml/L hyclone, 1.00ng/mL-15.00ng/mL
Activin A and 10-200ng/mL wnt3a；
Described culture medium B is made up of zooblast basal medium and solute；Described solute and at zooblast
Concentration in basal medium is as follows: 1.00ml/L-20.00ml/L hyclone and 1.00ng/mL-15.00ng/mL
activin A；
Described culture medium C is made up of zooblast basal medium and solute；Described solute and at zooblast
Concentration in basal medium is as follows: 0.50 × 10-5mol/L-2.0×10-5Mol/L retinoic acid,
10ng/ml-30ng/ml EGF、10ng/ml-100ng/ml bFGF、20ng/ml-200ng/ml Dkk1、
0.2mmol/L-10mmol/L glutamine, volume ratio are the non essential amino acid of 0.2%-5% and optional body
Long-pending than the B27 for 0.5%-5%；And wherein said zooblast basal medium is DMEM in high glucose culture medium
Or DMEM/F12 culture medium.
The most according to claim 1 by the test kit that mescenchymal stem cell induction is pancreatic stem cells, wherein
Described culture medium A is made up of zooblast basal medium and solute；Described solute and at zooblast
Concentration in basal medium is as follows: 4.75ml/L-5.25ml/L hyclone, 4.75ng/mL-5.25ng/mL
Activin A and 40-60ng/mL wnt3a；
Described culture medium B is made up of zooblast basal medium and solute；Described solute and at zooblast
Concentration in basal medium is as follows: 4.75ml/L-5.25ml/L hyclone and 4.75ng/mL-5.25ng/mL
activin A；
Described culture medium C is made up of zooblast basal medium and solute；Described solute and at zooblast
Concentration in basal medium is as follows: 0.95 × 10-5mol/L-1.05×10-5Mol/L retinoic acid,
19ng/ml-21ng/ml EGF、32ng/ml-64ng/ml bFGF、80ng/ml-120ng/ml Dkk1、
1.9mmol/L-2.1mmol/L the non essential amino acid that glutamine, volume ratio are 0.95%-1.05% and optional
The B27 that volume ratio is 1.9%-2.1%.
The most according to claim 2 by the test kit that mescenchymal stem cell induction is pancreatic stem cells, it is special
Levy and be:
Described culture medium A is made up of DMEM in high glucose culture medium and solute；Described solute and in culture medium A
In concentration as follows: 5ml/L hyclone, 5ng/mL activin A and 60ng/mL wnt3a；
Described culture medium B is made up of DMEM in high glucose culture medium and solute；Described solute and in culture medium A
In concentration as follows: 5ml/L hyclone and 5ng/mL activin A；
Described culture medium C is made up of DMEM/F12 culture medium and solute；Described solute and in culture medium B
Concentration as follows: 10-5Mol/L retinoic acid, 20ng/ml EGF, 60ng/ml bFGF, 100ng/ml Dkk1,
2mmol/L glutamine, volume ratio be 1% non essential amino acid and optional volume ratio be the B27 of 2%.
4. according to the reagent that being induced by mescenchymal stem cell described in any one of claim 1-3 is pancreatic stem cells
Box, it is characterised in that it also includes culture medium D or E, wherein
Culture medium D is made up of DMEM in high glucose culture medium and solute；Described solute and in culture medium D
Concentration is as follows: 5ml/L hyclone, 20ng/ml exendin-4,10ng/ml activin A, 10mmol/L Buddhist nun
Gram amide, volume ratio be 2% B27 and volume ratio be the N2 of 1%；
Culture medium E is made up of DMEM in high glucose culture medium and solute；Described solute and dense in culture medium E thereof
Spend as follows: 5ml/L hyclone, 20ng/ml exendin-4,15ng/ml FGF7,10mmol/L niacin amide,
Volume ratio be 2% B27 and volume ratio be the N2 of 1%.
5. according to the reagent that being induced by mescenchymal stem cell described in any one of claim 1-3 is pancreatic stem cells
Box, it is characterised in that described mescenchymal stem cell is fat mesenchymal stem cell.
The most according to claim 5 by the test kit that mescenchymal stem cell induction is pancreatic stem cells, it is special
Levy and be that described mescenchymal stem cell is the 3rd generation mescenchymal stem cell.
7., by the method that mescenchymal stem cell induction is pancreatic stem cells, it includes step: done by mesenchyme
Cell is successively by culture medium A, culture medium B and the culture medium C in the test kit described in any one of claim 1-3
Cultivating, obtain pancreatic stem cells, wherein said mescenchymal stem cell uses conventional method to obtain.
The most according to claim 7 by the method that mescenchymal stem cell induction is pancreatic stem cells, its feature
It is: described method comprises the steps:
1) mescenchymal stem cell that conventional method obtains is inoculated in described culture medium A, cultivates 1d；
2) step 1 will be completed) cell transfer in described culture medium B, cultivate 4-5d；
3) step 2 will be completed) cell transfer in described culture medium C, cultivate 4-6d, obtain pancreatic stem thin
Born of the same parents.
The most according to claim 8 by the method that mescenchymal stem cell induction is pancreatic stem cells, its feature
It being: in described step (1), described mescenchymal stem cell initial concentration in described culture medium A is 2 ×
105Individual/ml-1 × 106Individual/ml；In described method, the condition of culture of whole incubation is: at 37 DEG C, 50ml/L
CO2, relative air humidity be 95% incubator in cultivate.
10. according to the side that being induced by mescenchymal stem cell described in any one of claim 7-9 is pancreatic stem cells
Method, it also comprises the steps:
The pancreatic stem cells obtained is separately added into culture medium D in test kit as claimed in claim 4 or training
Supporting base E, every hole 2000 μ L, at 37 DEG C, 50ml/L CO2, relative air humidity be 95% incubator in train
Support 8d, every 2d suction abandon supernatant and add 2000 culture medium D new for μ L or E.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210371241.8A CN103710302B (en) | 2012-09-28 | 2012-09-28 | Prepare method and the special culture media combination thereof of pancreatic stem cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210371241.8A CN103710302B (en) | 2012-09-28 | 2012-09-28 | Prepare method and the special culture media combination thereof of pancreatic stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103710302A CN103710302A (en) | 2014-04-09 |
| CN103710302B true CN103710302B (en) | 2016-10-19 |
Family
ID=50403665
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210371241.8A Active CN103710302B (en) | 2012-09-28 | 2012-09-28 | Prepare method and the special culture media combination thereof of pancreatic stem cells |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103710302B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107389417A (en) * | 2017-03-30 | 2017-11-24 | 贵州省人民医院 | A kind of detection method of hAECs DED organization engineering skins Proliferation, Differentiation vigor |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101314766A (en) * | 2007-05-31 | 2008-12-03 | 中国医学科学院基础医学研究所 | Method for isolated culture of human fat mesenchyma stem cell and special culture medium thereof |
| CN101952415A (en) * | 2007-07-31 | 2011-01-19 | 生命扫描有限公司 | Differentiation of human embryonic stem cells |
| CN102048756A (en) * | 2009-11-04 | 2011-05-11 | 中国医学科学院基础医学研究所 | Use of human fat-derived mesenchymal stem cells in treatment of diseases in kidney and ocular fundus |
-
2012
- 2012-09-28 CN CN201210371241.8A patent/CN103710302B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101314766A (en) * | 2007-05-31 | 2008-12-03 | 中国医学科学院基础医学研究所 | Method for isolated culture of human fat mesenchyma stem cell and special culture medium thereof |
| CN101952415A (en) * | 2007-07-31 | 2011-01-19 | 生命扫描有限公司 | Differentiation of human embryonic stem cells |
| CN102048756A (en) * | 2009-11-04 | 2011-05-11 | 中国医学科学院基础医学研究所 | Use of human fat-derived mesenchymal stem cells in treatment of diseases in kidney and ocular fundus |
Non-Patent Citations (2)
| Title |
|---|
| 脂肪来源成体干细胞分化为内皮细胞的潜能;曹莹 等;《中国医学科学院学报》;20051231;第27卷(第6期);678-682 * |
| 非病毒诱导体系高效诱导脐带来源间充质干细胞向胰岛细胞分化;李晶等;《中国医学科学院学报》;20111120;第33卷(第6期);摘要、第676页左栏第2段-677页右栏第2段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103710302A (en) | 2014-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Oshima et al. | Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and c-Met by flow cytometric cell sorting | |
| Gao et al. | In vitro cultivation of islet-like cell clusters from human umbilical cord blood-derived mesenchymal stem cells | |
| Alessandri et al. | Isolation and culture of human muscle-derived stem cells able to differentiate into myogenic and neurogenic cell lineages | |
| US10358629B2 (en) | Regulating stem cells | |
| EP2273996B1 (en) | Human cardiovascular progenitor cells | |
| Phuc et al. | Differentiating of banked human umbilical cord blood-derived mesenchymal stem cells into insulin-secreting cells | |
| Lusis et al. | Isolation of clonogenic, long-term self renewing embryonic renal stem cells | |
| CN103184186A (en) | Preparation process for insulin-secreting cells and special medium composition used therein | |
| US20030186439A1 (en) | Self-renewing pluripotent hepatic stem cells | |
| CN101314766B (en) | Method for isolated culture of human fat mesenchyma stem cell and special culture medium thereof | |
| CN103834613B (en) | The method for preparing multipotency angiocarpy precursor and maintaining its cardiovascular differentiation capability | |
| Kawanabe et al. | The presence of ABCG2-dependent side population cells in human periodontal ligaments | |
| Shaer et al. | miR-375 induces human decidua basalis-derived stromal cells to become insulin-producing cells | |
| US20230126485A1 (en) | Pancreatic stem cells and uses thereof | |
| CN110392735A (en) | The maintenance and amplification of pancreatic progenitor cell | |
| CN107916248A (en) | From the hepatocyte differentiation method of human stem cells and liver cell | |
| CN103710302B (en) | Prepare method and the special culture media combination thereof of pancreatic stem cells | |
| Moshrefi et al. | Transplantation of differentiated umbilical cord mesenchymal cells under kidney capsule for control of type I diabetes in rat | |
| CN103881962A (en) | Method of establishing rat pancreatic duct epithelioid stem cell system | |
| Lan et al. | Islet-like clusters derived from skeletal muscle-derived stem/progenitor cells for autologous transplantation to control type 1 diabetes in mice | |
| JP4122365B2 (en) | Method for producing cells for transplantation | |
| CN103194424A (en) | Method for inducing embryonic stem cell into pancreatic tissue-like cells | |
| JP2006075022A (en) | Method for obtaining cell producing pancreatic hormone | |
| KR20190115454A (en) | Cell Products of Mammalian Insulin Producing Cells and Methods for Using the Same | |
| CN117448267A (en) | Mesenchymal stem cell construction method and application for osteoarthritis medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190202 Address after: 262700 Middle Section of Xiangyang Road, Yangkou Town, Shouguang City, Shandong Province Patentee after: Shouguang Jinwo Real Estate Co., Ltd. Address before: 100005 Dongdan No. 3, No. 5, Dongcheng District, Beijing Patentee before: Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200325 Address after: 266200 Room 601, building B, No. 168, Ningdong Road, Blue New Area, Jimo Provincial Economic Development Zone, Qingdao, Shandong Province Patentee after: QINGDAO GUOAOYUAN BIOENGINEERING TECHNOLOGY GROUP Co.,Ltd. Address before: 262700 Middle Section of Xiangyang Road, Yangkou Town, Shouguang City, Shandong Province Patentee before: Shouguang Jinwo Real Estate Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 266200 Room 601, building B, No. 168, Ningdong Road, Blue New Area, Jimo Provincial Economic Development Zone, Qingdao, Shandong Province Patentee after: Qingdao Hualing Aoyuan Bioengineering Technology Group Co.,Ltd. Address before: 266200 Room 601, building B, No. 168, Ningdong Road, Blue New Area, Jimo Provincial Economic Development Zone, Qingdao, Shandong Province Patentee before: QINGDAO GUOAOYUAN BIOENGINEERING TECHNOLOGY GROUP Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20210721 Address after: 266000 No.168 Ningdong Road, Blue New District, Jimo Economic Development Zone, Qingdao City, Shandong Province Patentee after: Qingdao Guoaoyuan Huasheng Biotechnology Group Co.,Ltd. Address before: Room 601, building B, 168 Ningdong Road, Blue New District, Jimo Provincial Economic Development Zone, Qingdao, Shandong 266200 Patentee before: Qingdao Hualing Aoyuan Bioengineering Technology Group Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 266000 No.168 Ningdong Road, Blue New District, Jimo Economic Development Zone, Qingdao City, Shandong Province Patentee after: Micro energy Life Technology Group Co.,Ltd. Address before: 266000 No.168 Ningdong Road, Blue New District, Jimo Economic Development Zone, Qingdao City, Shandong Province Patentee before: Qingdao Guoaoyuan Huasheng Biotechnology Group Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |